Allogene Therapeutics ALLO Accumulated Depreciation
Accumulated Depreciation at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment.
The official record: Allogene Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Allogene Therapeutics's accumulated depreciation.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Allogene Therapeutics's accumulated depreciation?
- Allogene Therapeutics (ALLO) reported accumulated depreciation of $75.4M in Q1 2026.
- How has Allogene Therapeutics's accumulated depreciation changed year-over-year?
- Allogene Therapeutics's accumulated depreciation increased by 14.9% year-over-year, from $65.64M to $75.4M.
- What is the long-term trend for Allogene Therapeutics's accumulated depreciation?
- Over 5 years (2020 to 2025), Allogene Therapeutics's accumulated depreciation has grown at a 41.2% compound annual growth rate (CAGR), from $12.91M to $72.53M.
- What does accumulated depreciation mean?
- Total accumulated depreciation on property, plant, and equipment since acquisition — represents the consumed portion of asset useful lives.